Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Midazolam Auto-Injector vs Seizalam in Healthy Adults
NCT04679623Phase 1Completed
- Sponsor
- Rafa Laboratories
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of midazolam in status epilepticus (SE) (2 arms), sponsored by Rafa Laboratories. Primary endpoints: Number of participants with local injection site changes at 28 days, Number of participants with systemic changes in physical exam at 28 days and 7 more. Started Jun 2021; status: completed.
02
Drugs
midazolam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT04679623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679623.